2003, Number 4
<< Back Next >>
Acta Med 2003; 1 (4)
Controversy above the osteopenia management
Zárate A, Saucedo R
Language: Spanish
References: 8
Page: 241-242
PDF size: 36.67 Kb.
Text Extraction
No Abstract
REFERENCES
Writing Group for the Women´s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women´s Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
The NIH Consensus development panel on osteoporosis prevention, diagnosis and therapy. JAMA 2001; 285: 785-9.
Zárate A, Hernández M, Morán C, Ángeles L. El enfoque moderno de la osteoporosis. Rev Fac Med 2003; 46: 49-51.
Kanis J. Diagnosis of osteoporosis and assessment of fracture risk. Lancet 2002; 359: 1929-35.
Marshall D. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996; 312: 1254-9.
Delmas P. Treatment of postmenopausal osteoporosis. Lancet 2002; 359: 2018-26.
Marcus R, Wong M, Heath H, Stock J. Antiresorptive treatment of postmenopausal osteoporosis: comparison of study designs and outcomes in large clinical trials with fracture as an endpoint. Endocrine Rev 2002; 23: 16-37.
Prestwood K, Guness M, Muchmore D, Lu Y, Wong M, Raisz L. A comparison of the effects of raloxifene and estrogens on bone in postmenopausal women. J Clin Endocrinol Metab 2000; 85: 2197-252.
Full text